MD1716B2 - Use of melatonin for treatment of patients dependent on benzodiazepine - Google Patents

Use of melatonin for treatment of patients dependent on benzodiazepine

Info

Publication number
MD1716B2
MD1716B2 MD97-0254A MD970254A MD1716B2 MD 1716 B2 MD1716 B2 MD 1716B2 MD 970254 A MD970254 A MD 970254A MD 1716 B2 MD1716 B2 MD 1716B2
Authority
MD
Moldova
Prior art keywords
treatment
melatonin
benzodiazepine
benzodiazepinic
dependence
Prior art date
Application number
MD97-0254A
Other languages
Romanian (ro)
Other versions
MD970254A (en
MD1716C2 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of MD970254A publication Critical patent/MD970254A/en
Publication of MD1716B2 publication Critical patent/MD1716B2/en
Publication of MD1716C2 publication Critical patent/MD1716C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to the melatonin use for treatment of polymedicinal dependence, for treatments of the patient with symptoms of tolerance, dependence on benzodiazepinic medicines or of the patient with a state susceptible of calmness by administration of a benzodiazepinic medicine, simultaneously preventing appearance to him of the symptoms of dependence, tolerance or excess of benzodiazepinic medicines. Claims: 8
MD97-0254A 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine MD1716C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (3)

Publication Number Publication Date
MD970254A MD970254A (en) 1999-05-31
MD1716B2 true MD1716B2 (en) 2001-08-31
MD1716C2 MD1716C2 (en) 2002-02-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0254A MD1716C2 (en) 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine

Country Status (22)

Country Link
JP (1) JP4516159B2 (en)
CN (1) CN1083263C (en)
AT (1) AT408188B (en)
AU (1) AU695366B2 (en)
BG (1) BG62876B1 (en)
BR (1) BR9607169A (en)
CZ (1) CZ291349B6 (en)
DK (1) DK176081B1 (en)
EE (1) EE03384B1 (en)
FI (1) FI119586B (en)
IS (1) IS1980B (en)
LU (1) LU90118B1 (en)
LV (1) LV11940B (en)
MD (1) MD1716C2 (en)
NO (1) NO312814B1 (en)
NZ (1) NZ298878A (en)
PL (1) PL183148B1 (en)
SI (1) SI9620022A (en)
SK (1) SK284521B6 (en)
TR (1) TR199700723T1 (en)
TW (1) TW483757B (en)
WO (1) WO1996023496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016918A (en) 2000-01-05 2004-03-23 Neurim Pharma 1991 Process and formulation for treating antihypertensive resistance and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
CA2861111C (en) 2012-01-26 2021-11-23 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2805376T3 (en) 2012-12-18 2021-02-11 Vanda Pharmaceuticals Inc Tasimelteon for treating circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3777842A1 (en) * 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229490T2 (en) * 1991-05-09 2000-02-17 Neurim Pharma 1991 Medicines containing melatonin
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE

Also Published As

Publication number Publication date
PL183148B1 (en) 2002-05-31
MD970254A (en) 1999-05-31
DK176081B1 (en) 2006-04-18
NZ298878A (en) 1999-05-28
SK284521B6 (en) 2005-05-05
BG62876B1 (en) 2000-10-31
SK103097A3 (en) 1998-01-14
AU4457496A (en) 1996-08-21
CZ240597A3 (en) 1998-01-14
LV11940B (en) 1998-05-20
AU695366B2 (en) 1998-08-13
SI9620022A (en) 1998-10-31
LU90118B1 (en) 1997-11-13
IS1980B (en) 2005-01-14
ATA901396A (en) 2001-02-15
CZ291349B6 (en) 2003-02-12
TR199700723T1 (en) 1998-02-21
CN1172431A (en) 1998-02-04
CN1083263C (en) 2002-04-24
IS4532A (en) 1997-07-25
FI119586B (en) 2009-01-15
JP4516159B2 (en) 2010-08-04
NO312814B1 (en) 2002-07-08
FI973185A (en) 1997-09-30
PL321630A1 (en) 1997-12-08
NO973531D0 (en) 1997-07-31
TW483757B (en) 2002-04-21
BG101803A (en) 1998-04-30
EE03384B1 (en) 2001-04-16
AT408188B (en) 2001-09-25
NO973531L (en) 1997-09-30
LV11940A (en) 1998-01-20
EE9700166A (en) 1998-02-16
WO1996023496A1 (en) 1996-08-08
DK89697A (en) 1997-07-30
BR9607169A (en) 1997-11-11
FI973185A0 (en) 1997-07-31
MD1716C2 (en) 2002-02-28
JPH10513177A (en) 1998-12-15
MX9705856A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
ES2165910T3 (en) NASAL AND OCULAR CETAMINE ADMINISTRATION FOR THE TREATMENT OF PAIN AND FOR DETOXIFICATION.
PT613371E (en) NEW COMBINATION OF FORMOTEROL AND BUDSONIDO
PT913156E (en) USE OF PROTEIN C ACTIVATED TO TREAT HYPERCERAGULATE STATES ASSOCIATED WITH SEPSIA
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
NO951592D0 (en) Process for the preparation of a transdermal therapeutic system
HU9301978D0 (en) Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin
NO20101190L (en) Use of buprenorphine in the manufacture of a medicament
NO306377B1 (en) Dosage form for delivery of a drug
CZ176495A3 (en) The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes
HUT77380A (en) Use of a pharmaceutical combination for the treatment of multiple sclerosis (ms) and other demyelinating conditions
BG106171A (en) Compositions and uses of et743 for treating cancer
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
BR0009380A (en) Improved cancer treatment with temozozomide
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
JPS6483020A (en) Medicinal composition for preventing or treating aids
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
HUP9900627A2 (en) Use of melatonin for producing pharmaceutical compositions suitable for treating patients suffering from drug addiction
Hole et al. Special depression treatment wards in the Federal Republic of Germany: A survey.
UA29589A (en) “inhapin” broncholytic drug
Cheng Benefits of combination therapy confirmed
UA10754A (en) Method for therapy of arterial hypertensions of various geneses
EP1264601A3 (en) Treatment of a coronary condition by delivery of therapeutics to the pericardial space

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees